Beyond Response: dMMR/MSI-H Outcomes in GI Immunotherapy

This podcast was funded by GSK who were not involved in its creation or development.

In the first episode of this ‘Beyond Response’ podcast series, host Sue Saville is joined by Kai-Keen Shiu, Thierry André, and Jérémie Lefevre to discuss the current landscape of biomarker testing in gastrointestinal cancers, with a focus on colorectal cancer. The panel considers how mismatch repair deficiency (dMMR)/microsatellite instability-high (MSI-H) status is changing patient pathways and where testing falls short in everyday practice.

Topics covered:

• The typical patient pathway in gastrointestinal cancers before biomarker testing, including the surgical perspective 

• The characteristics, frequency, and diagnosis of dMMR/MSI-H cancers 

• How dMMR/MSI-H status has shaped treatment in metastatic and early-stage colorectal cancer 

• The impact of a dMMR/MSI-H diagnosis on surgical decision-making 

• Where biomarker testing ideally fits in patient pathways and the real-world limitations to testing 

1. University College London Hospitals, UK
2. UCL Cancer Institute, London, UK
3. Hospital Saint-Antoine, Paris, France
4. Sorbonne Université, Paris, France  

Independent Healthcare Communications Specialist